On May 6, 2024, Context Therapeutics Inc., closed the transaction. As a part of the transaction, the company expects placement offering expenses will be approximately $5,200,000.
Context Therapeutics Inc.
Equities
US21077P1084
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |